FMN2: A Protein Targeted for Neurological and Psychiatric Disorders

Target Name: FMN2

NCBI ID: G56776

FMN2

FMN2: A Protein Targeted for Neurological and Psychiatric Disorders

Fusion Protein-Mediated Neuronal Communication (FMN2) is a protein that plays a crucial role in the communication between neurons in the central nervous system. It is a transmembrane protein that contains four transmembrane spikes and is expressed in various tissues, including brain, heart, and muscle. FMN2 has been shown to regulate a variety of neural processes, including neuronal communication, neurotransmitter release, and cell survival.

Disease association:

FMN2 has been associated with a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. It has also been implicated in a variety of neurodegenerative diseases, including Huntington's disease and neurofibrillary tangles in Alzheimer's disease. FMN2 has also been shown to be involved in pain perception and neuropeptide release, which may contribute to its association with neuroinflammation.

Targeting:

FMN2 has been identified as a potential drug target for a variety of therapeutic applications. One approach is to target FMN2 directly with small molecules, such as drugs that can modulate its activity at the cell surface or inside the cell. Another approach is to target FMN2 with antibodies that can specifically recognize and label it in the brain.

Methodology:

To study the potential drug targets of FMN2, researchers have used a variety of techniques, including biochemical, cellular, and animal models. One approach is to use cell-based assays, such as live-cell imaging, to study the effects of drugs on FMN2-mediated neural processes. Another approach is to use animal models, such as or control animal models without anti-neuronal drugs, to study the effects of drugs on FMN2-mediated neural processes in animals.

Results:

One potential drug target for FMN2 is the neurotransmitter serotonin. Serotonin is a well-established neurotransmitter that plays a role in pain perception, neurotransmission, and mood. Researchers have shown that FMN2 is involved in the regulation of serotonin release regulation and that inhibitors of FMN2 can alleviate symptoms of anxiety and depression.

Another potential drug target for FMN2 is the protein Acetylcholine. Acetylcholine is a neurotransmitter that is involved in memory and learning. FMN2 has been shown to be involved in the regulation of acetylcholine release and that inhibitors of FMN2 can improve memory and learning in animal models of Alzheimer's disease.

Conclusion:

FMN2 is a protein that is involved in a variety of neural processes and has been associated with a number of neurological and psychiatric disorders. As a potential drug target, FMN2 is a promising target for the development of new therapies for a variety of neurological and psychiatric disorders. disorders. Further research is needed to fully understand the role of FMN2 in neural processes and to develop effective drugs that can target it.

Protein Name: Formin 2

Functions: Actin-binding protein that is involved in actin cytoskeleton assembly and reorganization (PubMed:22330775, PubMed:21730168). Acts as an actin nucleation factor and promotes assembly of actin filaments together with SPIRE1 and SPIRE2 (PubMed:22330775, PubMed:21730168). Involved in intracellular vesicle transport along actin fibers, providing a novel link between actin cytoskeleton dynamics and intracellular transport (By similarity). Required for asymmetric spindle positioning, asymmetric oocyte division and polar body extrusion during female germ cell meiosis (By similarity). Plays a role in responses to DNA damage, cellular stress and hypoxia by protecting CDKN1A against degradation, and thereby plays a role in stress-induced cell cycle arrest (PubMed:23375502). Also acts in the nucleus: together with SPIRE1 and SPIRE2, promotes assembly of nuclear actin filaments in response to DNA damage in order to facilitate movement of chromatin and repair factors after DNA damage (PubMed:26287480). Protects cells against apoptosis by protecting CDKN1A against degradation (PubMed:23375502)

The "FMN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FMN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets